Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Director Thomas R. Lawrence sold 6,000 shares of the company’s stock in a transaction that occurred on Friday, April 7th. The shares were sold at an average price of $6.40, for a total value of $38,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) traded down 3.5424% during midday trading on Friday, hitting $6.0286. The stock had a trading volume of 2,275 shares. The firm’s market cap is $96.54 million. The stock has a 50-day moving average price of $6.38 and a 200 day moving average price of $5.72. Cumberland Pharmaceuticals, Inc. has a 12-month low of $4.27 and a 12-month high of $7.48.
Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its quarterly earnings data on Tuesday, March 7th. The specialty pharmaceutical company reported $0.05 earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a negative net margin of 0.14% and a positive return on equity of 1.46%. The company earned $9.08 million during the quarter. On average, equities analysts anticipate that Cumberland Pharmaceuticals, Inc. will post $0.09 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Cumberland Pharmaceuticals, Inc. (CPIX) Director Sells $38,400.00 in Stock” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.chaffeybreeze.com/2017/04/21/thomas-r-lawrence-sells-6000-shares-of-cumberland-pharmaceuticals-inc-cpix-stock-updated.html.
Hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its stake in shares of Cumberland Pharmaceuticals by 4.0% in the fourth quarter. Renaissance Technologies LLC now owns 257,000 shares of the specialty pharmaceutical company’s stock valued at $1,414,000 after buying an additional 9,900 shares in the last quarter. Stonepine Capital Management LLC boosted its stake in shares of Cumberland Pharmaceuticals by 91.4% in the fourth quarter. Stonepine Capital Management LLC now owns 619,538 shares of the specialty pharmaceutical company’s stock valued at $3,407,000 after buying an additional 295,791 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Cumberland Pharmaceuticals by 0.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 852,976 shares of the specialty pharmaceutical company’s stock valued at $4,691,000 after buying an additional 2,791 shares in the last quarter. 34.17% of the stock is owned by institutional investors.
Cumberland Pharmaceuticals Company Profile
Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company’s product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H.
Receive News & Ratings for Cumberland Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.